Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada
Abstract
:1. Introduction
2. Materials and Methods
Clinic Description
3. Results
3.1. Baseline Characteristics
3.2. Geriatric Oncology Clinic Characteristics, Findings and Recommendations
3.3. Cancer Treatment Status and Characteristics Post-CGA
3.4. ER Visits and Hospitalizations
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kadambi, S.; Loh, K.P.; Dunne, R.; Magnuson, A.; Maggiore, R.; Zittel, J.; Flannery, M.; Inglis, J.; Gilmore, N.; Mohamed, M.; et al. Older Adults with Cancer and Their Caregivers—Current Landscape and Future Directions for Clinical Care. Nat. Rev. Clin. Oncol. 2020, 17, 742–755. [Google Scholar] [CrossRef]
- Mohile, S.; Dale, W.; Hurria, A. Geriatric Oncology Research to Improve Clinical Care. Nat. Rev. Clin. Oncol. 2012, 9, 571–578. [Google Scholar] [CrossRef]
- Balducci, L.; Beghe, C. The Application of the Principles of Geriatrics to the Management of the Older Person with Cancer. Crit. Rev. Oncol. Hematol. 2000, 35, 147–154. [Google Scholar] [CrossRef]
- Soo, W.-K.; King, M.; Pope, A.; Parente, P.; Darzins, P.; Davis, I.D. Integrated Geriatric Assessment and Treatment (INTEGERATE) in Older People with Cancer Planned for Systemic Anticancer Therapy. J. Clin. Oncol. 2020, 38, 12011. [Google Scholar] [CrossRef]
- Scher, K.S.; Hurria, A. Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress. J. Clin. Oncol. 2012, 30, 2036–2038. [Google Scholar] [CrossRef]
- Talarico, L.; Chen, G.; Pazdur, R. Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration. J. Clin. Oncol. 2004, 22, 4626–4631. [Google Scholar] [CrossRef] [PubMed]
- Okoli, G.N.; Stirling, M.; Racovitan, F.; Lam, O.L.; Reddy, V.K.; Copstein, L.; Hsu, T.; Abou-Setta, A.M.; Dawe, D.E. Integration of Geriatric Assessment into Clinical Oncology Practice: A Scoping Review. Curr. Probl. Cancer 2021, 45, 100699. [Google Scholar] [CrossRef] [PubMed]
- López-Otín, C.; Pietrocola, F.; Roiz-Valle, D.; Galluzzi, L.; Kroemer, G. Meta-Hallmarks of Aging and Cancer. Cell Metab. 2023, 35, 12–35. [Google Scholar] [CrossRef] [PubMed]
- Bumanlag, I.M.; Jaoude, J.A.; Rooney, M.K.; Taniguchi, C.M.; Ludmir, E.B. Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. Semin. Radiat. Oncol. 2022, 32, 125–134. [Google Scholar] [CrossRef] [PubMed]
- 2008 National Health Interview Survey. Percent of US Adults 55 and Over with Chronic Conditions. 2008, p. 76. Available online: https://ftp.cdc.gov/pub/health_statistics/nchs/Dataset_Documentation/NHIS/2008/srvydesc.pdf (accessed on 28 January 2025).
- Hurria, A.; Levit, L.A.; Dale, W.; Mohile, S.G.; Muss, H.B.; Fehrenbacher, L.; Magnuson, A.; Lichtman, S.M.; Bruinooge, S.S.; Soto-Perez-de-Celis, E.; et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. J. Clin. Oncol. 2015, 33, 3826–3833. [Google Scholar] [CrossRef]
- Kristjansson, S.R.; Farinella, E.; Gaskell, S.; Audisio, R.A. Surgical Risk and Post-Operative Complications in Older Unfit Cancer Patients. Cancer Treat. Rev. 2009, 35, 499–502. [Google Scholar] [CrossRef] [PubMed]
- Dale, W.; Klepin, H.D.; Williams, G.R.; Alibhai, S.M.H.; Bergerot, C.; Brintzenhofeszoc, K.; Hopkins, J.O.; Jhawer, M.P.; Katheria, V.; Loh, K.P.; et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J. Clin. Oncol. 2023, 41, 4293–4312. [Google Scholar] [CrossRef] [PubMed]
- Caillet, P.; Laurent, M.; Bastuji-Garin, S.; Liuu, E.; Lagrange, J.-L.; Culine, S.; Canoui-Poitrine, F.; Paillaud, E. Optimal Management of Elderly Cancer Patients: Usefulness of the Comprehensive Geriatric Assessment. Clin. Interv. Aging 2014, 9, 1645–1660. [Google Scholar] [CrossRef] [PubMed]
- Stuck, A.E.; Siu, A.L.; Wieland, G.D.; Rubenstein, L.Z.; Adams, J. Comprehensive Geriatric Assessment: A Meta-Analysis of Controlled Trials. Lancet 1993, 342, 1032–1036. [Google Scholar] [CrossRef] [PubMed]
- Frese, T.; Deutsch, T.; Keyser, M.; Sandholzer, H. In-Home Preventive Comprehensive Geriatric Assessment (CGA) Reduces Mortality—A Randomized Controlled Trial. Arch. Gerontol. Geriatr. 2012, 55, 639–644. [Google Scholar] [CrossRef] [PubMed]
- Extermann, M.; Aapro, M.; Bernabei, R.; Cohen, H.J.; Droz, J.-P.; Lichtman, S.; Mor, V.; Monfardini, S.; Repetto, L.; Sørbye, L.; et al. Use of Comprehensive Geriatric Assessment in Older Cancer Patients. Crit. Rev. Oncol. Hematol. 2005, 55, 241–252. [Google Scholar] [CrossRef]
- Li, D.; Sun, C.-L.; Kim, H.; Soto-Perez-de-Celis, E.; Chung, V.; Koczywas, M.; Fakih, M.; Chao, J.; Cabrera Chien, L.; Charles, K.; et al. Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. JAMA Oncol. 2021, 7, e214158. [Google Scholar] [CrossRef] [PubMed]
- Mohile, S.G.; Mohamed, M.R.; Xu, H.; Culakova, E.; Loh, K.P.; Magnuson, A.; Flannery, M.A.; Obrecht, S.; Gilmore, N.; Ramsdale, E.; et al. Evaluation of Geriatric Assessment and Management on the Toxic Effects of Cancer Treatment (GAP70+): A Cluster-Randomised Study. Lancet 2021, 398, 1894–1904. [Google Scholar] [CrossRef] [PubMed]
- Kalsi, T.; Babic-Illman, G.; Ross, P.J.; Maisey, N.R.; Hughes, S.; Fields, P.; Martin, F.C.; Wang, Y.; Harari, D. The Impact of Comprehensive Geriatric Assessment Interventions on Tolerance to Chemotherapy in Older People. Br. J. Cancer 2015, 112, 1435–1444. [Google Scholar] [CrossRef] [PubMed]
- Yesavage, J.A.; Brink, T.L.; Rose, T.L.; Lum, O.; Huang, V.; Adey, M.; Leirer, V.O. Development and Validation of a Geriatric Depression Screening Scale: A Preliminary Report. J. Psychiatr. Res. 1982, 17, 37–49. [Google Scholar] [CrossRef]
- Wallace, M.; Shelkey, M.; Hartford Institute for Geriatric Nursing. Katz Index of Independence in Activities of Daily Living (ADL). Urol. Nurs. 2007, 27, 93–94. [Google Scholar] [PubMed]
- Graf, C. The Lawton Instrumental Activities of Daily Living Scale. AJN Am. J. Nurs. 2008, 108, 52–62. [Google Scholar] [CrossRef] [PubMed]
- Rockwood, K.; Theou, O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. Can. Geriatr. J. 2020, 23, 254–259. [Google Scholar] [CrossRef]
- Hurria, A.; Togawa, K.; Mohile, S.G.; Owusu, C.; Klepin, H.D.; Gross, C.P.; Lichtman, S.M.; Gajra, A.; Bhatia, S.; Katheria, V.; et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J. Clin. Oncol. 2011, 29, 3457–3465. [Google Scholar] [CrossRef] [PubMed]
- Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.; Chertkow, H. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [Google Scholar] [CrossRef] [PubMed]
- Kurlowicz, L.; Wallace, M. The Mini-Mental State Examination (MMSE). J. Gerontol. Nurs. 1999, 25, 8–9. [Google Scholar] [CrossRef] [PubMed]
- Storey, J.E.; Rowland, J.T.J.; Conforti, D.A.; Dickson, H.G. The Rowland Universal Dementia Assessment Scale (RUDAS): A Multicultural Cognitive Assessment Scale. Int. Psychogeriatr. 2004, 16, 13–31. [Google Scholar] [CrossRef]
- Borson, S.; Scanlan, J.; Brush, M.; Vitaliano, P.; Dokmak, A. The Mini-Cog: A Cognitive “vital Signs” Measure for Dementia Screening in Multi-Lingual Elderly. Int. J. Geriatr. Psychiatry 2000, 15, 1021–1027. [Google Scholar] [CrossRef] [PubMed]
- Verduzco-Aguirre, H.C.; Navarrete-Reyes, A.P.; Chavarri-Guerra, Y.; Ávila-Funes, J.A.; Soto-Perez-de-Celis, E. The Effect of a Geriatric Oncology Clinic on Treatment Decisions in Mexican Older Adults With Cancer. J. Am. Geriatr. Soc. 2019, 67, 992–997. [Google Scholar] [CrossRef]
- Sourdet, S.; Brechemier, D.; Steinmeyer, Z.; Gerard, S.; Balardy, L. Impact of the Comprehensive Geriatric Assessment on Treatment Decision in Geriatric Oncology. BMC Cancer 2020, 20, 384. [Google Scholar] [CrossRef]
- Luciani, A.; Jacobsen, P.B.; Extermann, M.; Foa, P.; Marussi, D.; Overcash, J.A.; Balducci, L. Fatigue and Functional Dependence in Older Cancer Patients. Am. J. Clin. Oncol. 2008, 31, 424–430. [Google Scholar] [CrossRef] [PubMed]
- Corre, R.; Greillier, L.; Le Caër, H.; Audigier-Valette, C.; Baize, N.; Bérard, H.; Falchero, L.; Monnet, I.; Dansin, E.; Vergnenègre, A.; et al. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J. Clin. Oncol. 2016, 34, 1476–1483. [Google Scholar] [CrossRef] [PubMed]
- Garric, M.; Sourdet, S.; Cabarrou, B.; Steinmeyer, Z.; Gauthier, M.; Ysebaert, L.; Beyne-Rauzy, O.; Gerard, S.; Lozano, S.; Brechemier, D.; et al. Impact of a Comprehensive Geriatric Assessment on Decision-making in Older Patients with Hematological Malignancies. Eur. J. Haematol. 2021, 106, 616–626. [Google Scholar] [CrossRef]
- Magnuson, A.; Mohile, S.; Janelsins, M. Cognition and Cognitive Impairment in Older Adults with Cancer. Curr. Geriatr. Rep. 2016, 5, 213–219. [Google Scholar] [CrossRef] [PubMed]
Total | |
---|---|
(n = 100) | |
Age | |
Median (Range) | 80 (63–97) |
Sex | |
Female | 70 (70%) |
Male | 30 (30%) |
Cancer type (n = 106) a | |
Breast | 33 (31%) |
Gastrointestinal | 27 (25%) |
Skin | 14 (13%) |
Lung | 10 (9%) |
Malignant hematology | 8 (8%) |
Genitourinary | 8 (8%) |
Gynecologic | 3 (3%) |
Head and neck | 3 (3%) |
Cancer stage (n = 106) a | |
Early stage (I-III) | 52 (49%) |
Advanced stage (IV) | 49 (46%) |
No proven cancer—IPMN | 3 (3%) |
N/A—Suspected MDS or MDS/MPN overlap | 2 (2%) |
Number of active and past medical conditions | |
Median (Interquartile range) | 7 (5, 10) |
Pre-existing conditions of interest | |
Depression | 18 (18%) |
Delirium | 9 (9%) |
Dementia/cognitive impairment | 6 (6%) |
Number of current medications | |
Median (Interquartile range) | 7 (4, 10) |
Cancer treatment status at the time of CGA | |
On treatment b | 41 (41%) |
Considering treatment | 29 (29%) |
On surveillance | 25 (25%) |
Current treatment on hold | 5 (5%) |
Type of cancer treatment at time of CGA (n = 52) c | |
Endocrine therapy | 21 (40%) |
Chemotherapy | 16 (31%) |
Immunotherapy | 10 (19%) |
Targeted therapy | 4 (8%) |
Radiation | 1 (2%) |
Dosing of current treatment (n = 46) | |
Ideal dose | 27 (59%) |
Reduced | 16 (35%) |
Increased | 2 (4%) |
N/A | 1 (2%) |
Total | |
---|---|
(n = 100) | |
Proportion of patients seen | 100/103 (97%) |
Time frame seen, days | |
Median (Interquartile range) | 21 (14, 33) |
Sensitivity Analysis—Time frame seen, days (n = 94) d | |
Median (Interquartile range) | 18 (13, 31) |
Treatment candidate patients—Time frame seen, days (n = 33) | |
Median (Interquartile range) | 15 (10, 18) |
Patients seen within target requested | 54 (54%) |
Reasons not seen within target (n = 46) | |
Earliest slot available | 35 (76%) |
Clinic understaffed | 4 (9%) |
Patient/patient’s family requested to rebook | 2 (4%) |
Clinic closure | 2 (4%) |
Delayed due to awaiting investigations | 1 (2%) |
Administrative delay | 1 (2%) |
Unknown | 1 (2%) |
Specialty of referring physician | |
Medical oncology | 77 (77%) |
Surgery | 13 (13%) |
Radiation oncology | 6 (6%) |
Malignant hematology | 3 (3%) |
Palliative medicine | 1 (1%) |
Reasons for referral (n = 150) e | |
Cognitive decline | 48 (32%) |
Treatment candidate | 33 (22%) |
Functional decline/Frailty | 22 (15%) |
Mobility/Falls | 19 (13%) |
Multi-morbidity | 8 (5%) |
Polypharmacy | 5 (3%) |
Mood/Behaviour | 3 (2%) |
Medical optimization prior to surgery | 2 (1%) |
General assessment | 2 (1%) |
Other f | 8 (5%) |
Pre-assessments | |
Pharmacy (n = 100) | 86 (86%) |
Occupational therapy (n = 54) g | 34 (63%) |
Nursing (n = 46) g | 36 (78%) |
Abnormal cognitive screen result | |
MOCA (n = 60) | 46 (77%) |
RUDAS (n = 16) | 5 (31%) |
MMSE (n = 5) | 2 (40%) |
Mini-Cog (n = 2) | 0 (00%) |
Abnormal GDS score (n = 78) h | 20 (26%) |
Clinical Frailty Score (n = 76) | |
Median (Interquartile range) | 5 (4, 6) |
ADL score deficits | |
Median (Interquartile range) | 0 (0, 2) |
IADL score deficits | |
Median (Interquartile range) | 2.5 (1, 5) |
New diagnoses (n = 84) i | |
Cognition | 55 (65%) |
Cardiac | 10 (12%) |
Depression | 7 (8%) |
Neurological | 6 (7%) |
Renal | 3 (4%) |
Endocrine | 2 (2%) |
Respiratory | 1 (1%) |
Type of specialist physician referrals (n = 24) j | |
Psychiatry | 6 (25%) |
Cardiology | 4 (17%) |
Ophthalmology | 4 (17%) |
Palliative care | 3 (13%) |
Neurology | 3 (13%) |
Urology | 1 (4%) |
Rheumatology | 1 (4%) |
Thromboembolism clinic | 1 (4%) |
Urogynecology | 1 (4%) |
Medication changes made | 47 (47%) |
Tests requested | |
Labs | 47 (47%) |
Imaging | 41 (41%) |
Cardiac tests | 18 (18%) |
EMG | 1 (1%) |
Total | |
---|---|
(n = 100) | |
Continuation of treatment after CGA (n = 46) | 35 (76%) |
Continuation of treatment and started new treatment after CGA (n = 46) | 3 (7%) |
Only started a new treatment after CGA (n = 54) | 29 (54%) |
Patients not on treatment before or after CGA | 22 (22%) |
Patients referred to determine suitability for treatment | |
Recommendations for/against cancer treatment (n = 33) k | |
Suitable for treatment | 16 (48%) |
Suitable for treatment with modification | 10 (30%) |
Concern/against treatment | 7 (21%) |
Referring MD that followed through with the recommendation (n = 33) | 31 (94%) |
Cancer treatment status within 6 months after CGA (n = 33) | |
On treatment | 25 (76%) |
Not on treatment | 8 (24%) |
Type of cancer treatment within 6 months after CGA (n = 33) l | |
Chemotherapy | 17 (50%) |
Immunotherapy | 6 (18%) |
Endocrine therapy | 3 (9%) |
Radiation | 4 (12%) |
Surgery | 4 (12%) |
Targeted therapy | 1 (3%) |
Dosing of treatment (n = 25) | |
No change | 9 (36%) |
Reduced | 10 (40%) |
Increased | 0 (0%) |
N/A | 6 (24%) |
Patients not referred to determine suitability for treatment | |
Cancer treatment status within 6 months after CGA (n = 67) | |
On treatment | 44 (66%) |
Not on treatment | 23 (34%) |
Type of cancer treatment within 6 months after CGA (n = 50) m | |
Chemotherapy | 11 (22%) |
Immunotherapy | 8 (16%) |
Endocrine therapy | 21 (42%) |
Radiation | 3 (6%) |
Surgery | 3 (6%) |
Targeted therapy | 4 (8%) |
Dosing of treatment (n = 43) | |
No change | 24 (56%) |
Reduced | 13 (30%) |
Increased | 2 (5%) |
N/A | 4 (9%) |
Total | |
---|---|
(n = 100) | |
ER visits within 6 months of CGA | |
Number of ER visits per patient | |
Median (Interquartile range) | 0 (0, 1) |
Reason for first ER visit (n = 34) n | |
Cancer-related | 12 (35%) |
Comorbidity-related | 12 (35%) |
Treatment-related | 4 (12%) |
Infection-related | 4 (12%) |
Other | 2 (6%) |
Reason for second/third ER visit (n = 10) o | |
Cancer-related | 3 (30%) |
Comorbidity-related | 3 (30%) |
Treatment-related | 1 (10%) |
Infection-related | 3 (30%) |
Hospitalizations within 6 months of CGA | |
Number of hospitalizations per patient | |
Median (Interquartile range) | 0 (0, 1) |
Length of stay, days (n = 40) | |
Median (Interquartile range) | 7 (3, 12) |
Reason for first hospitalization (n = 32) p | |
Cancer-related | 16 (50%) |
Infection-related | 7 (22%) |
Comorbidity-related | 6 (19%) |
Treatment-related | 3 (9%) |
Discharge location after first hospitalization (n = 30) | |
Home with support services | 10 (33%) |
Home without support services | 12 (40%) |
Palliative care unit (Sunnybrook) | 4 (13%) |
Deceased | 3 (10%) |
Unknown | 1 (3%) |
Reason for second/third hospitalization (n = 10) q | |
Cancer-related | 4 (40%) |
Comorbidity-related | 4 (40%) |
Infection-related | 1 (10%) |
Treatment-related | 1 (10%) |
Discharge location after second/third hospitalization (n = 10) q | |
Home with support services | 1 (10%) |
Home without support services | 3 (30%) |
Rehab facility | 2 (20%) |
Deceased | 4 (4%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Menjak, I.B.; Campos, K.; Pasetka, M.; Budden, A.; Curle, E.; Gibson, L.; Szumacher, E.; Mehta, R. Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Curr. Oncol. 2025, 32, 89. https://doi.org/10.3390/curroncol32020089
Menjak IB, Campos K, Pasetka M, Budden A, Curle E, Gibson L, Szumacher E, Mehta R. Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Current Oncology. 2025; 32(2):89. https://doi.org/10.3390/curroncol32020089
Chicago/Turabian StyleMenjak, Ines B., Khloe Campos, Mark Pasetka, Arlene Budden, Elaine Curle, Leslie Gibson, Ewa Szumacher, and Rajin Mehta. 2025. "Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada" Current Oncology 32, no. 2: 89. https://doi.org/10.3390/curroncol32020089
APA StyleMenjak, I. B., Campos, K., Pasetka, M., Budden, A., Curle, E., Gibson, L., Szumacher, E., & Mehta, R. (2025). Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Current Oncology, 32(2), 89. https://doi.org/10.3390/curroncol32020089